Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 44 of 183 for:    RET

AUY922 in Patient With Stage IV NSCLC (NSCLC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01922583
Recruitment Status : Completed
First Posted : August 14, 2013
Last Update Posted : July 18, 2018
Sponsor:
Information provided by (Responsible Party):
National Taiwan University Hospital

Brief Summary:
This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.

Condition or disease Intervention/treatment Phase
Non-small Cell Lung Cancer (NSCLC) Drug: AUY922 Phase 2

Detailed Description:

Study Design:

This is an open-label, single-arm, multicenter phase II trial in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC (n = 9 x 7)

Objectives:

Primary objective(s):

To define the objective response rate by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC

Secondary objective(s):

(1) To define the disease control rate (complete response + partial response + stable disease >=24 weeks) of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (2) To determine the progression-free survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC. (3) To determine the overall survival of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, KRAS, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC.

Exploratory Objective(s):

To study the pharmacodynamics of circulating tumor cells and plasma proteins.

Planned number of subjects: A total of 63 patients for the first stage of this study in 1 - 3 centers in Taiwan.

Patient population:

  1. Stage IV (by AJCC 7th edition) NSCLC.
  2. EGFR T790M mutation; EGFR exon 20 and other uncommon mutation; HER2 mutation; BRAF mutation; ALK translocation; ROS1 translocation; or RET translocation in tumor samples.
  3. One line of prior systemic therapy.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 31 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multi-center Phase II Study of AUY922 in Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) With Driver Molecular Alterations Other Than Sensitive EGFR Mutation, Who Have Progressed After One Line of Systemic Therapy
Actual Study Start Date : January 2014
Actual Primary Completion Date : February 2017
Actual Study Completion Date : February 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Vial
AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
Drug: AUY922
AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression




Primary Outcome Measures :
  1. Objective response rate [ Time Frame: Patients will be followed up for 2 years(post disease progression) ]
    To define the by RECIST 1.1 of AUY922 in patients with stage IV EGFR T790M, EGFR exon 20 and other uncommon, HER2, or BRAF-mutated; ALK, ROS1, or RET-rearranged NSCLC


Secondary Outcome Measures :
  1. Efficacy, progression-free survival (PFS) [ Time Frame: Patients will be followed up for PFS and OS for 2 years.(post disease progression) ]

    Patients will be followed for progression-free survival (PFS) and overall survival (OS) which will be analyzed by using a Kaplan-Meier curve.

    Patients will be followed up for PFS and OS for 2 years.


  2. overall survival (OS) [ Time Frame: Patients will be followed up for OS for 2 years.(post disease progression) ]
    Patients will be followed for overall survival (OS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Histologically or cytologically proven diagnosis of stage IV NSCLC (AJCC 7th) which had been treated with one systemic therapy.
  • One of the molecular alterations as follows:

    • EGFR mutations in exon 20 T790M.
    • EGFR mutations in exon 20; in-frame duplication and/or insertion (e.g. A767_V769dupASV or H773_V774insH) or point mutations other than T790M; or other uncommon mutations.
    • HER2 mutation in exon 20; in-frame duplication and/or insertion (e.g. YVMA 776-779 ins).
    • BRAF mutation in exon 15; point mutation (e.g. V600E) or in exon 11; point mutation (e.g. G469A, D594G).
    • ALK translocation resulting in EML4-ALK, KIF5B-ALK, or TFG-ALK fusion as determined by an ALK break apart FISH assay and defined by an increase in the distance of 5' and 3' ALK probes (split 5'-3') or the loss of the 5' probe (single 3'). Positive ALK results from other methods such as immunohistochemistry (IHC) or reverse transcriptase polymerase chain reaction testing may also be acceptable.
    • ROS1 translocation resulting in CD74-ROS1 or SLC34A2-ROS1, etc.
    • RET translocation resulting in KIF5B-RET fusion, etc.
  • Patients with brain metastases are eligible if treated and neurologically stable for at least 2 weeks and is not taking any steroid.
  • Any prior chemotherapy, targeted therapy (monoclonal antibodies), or major surgeries must have had completed at least 4 weeks before initiation of study medication. Any prior targeted therapy (tyrosine kinase inhibitors), radiotherapy or minor surgeries must have had completed at least 2 weeks before initiation of study medication. Any acute toxicity must have recovered to <=grade 1 (except for alopecia).
  • Patients must have measurable or evaluable disease as per RECIST version 1.1.
  • 20 years of age or older
  • ECOG performance status 0-2
  • Adequate organ function as defined by the following criteria:

    • Bone marrow function
    • Hemoglobin >=8.0 g/dL
    • Absolute neutrophil count (ANC) >=1500/uL
    • Platelets >=100,000/uL
    • Hepatic function
    • Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) <=3.0 x upper limit of normal (ULN) or AST and ALT <=5.0 x ULN if there is liver metastasis
    • Total serum bilirubin <=1.5 x ULN Renal function
    • Creatinine <= 1.5 x ULN or creatinine clearance >=45 mL/min
  • Able to communicate well with the investigator, to understand and comply with the requirements of the study. Understand and sign the written informed consent.
  • Patients must use effective methods of contraception during the study period and for at least 90 days following study completion (excluding surgically sterile male patients, surgically sterile or postmenopausal female patients).

Exclusion Criteria:

  • Currently on other therapeutic clinical trials
  • Prior treatment of HSP90 inhibitors
  • Any of the following within 3 months before initiation of study medication

    • Myocardial infarction
    • Unstable angina
    • Coronary artery bypass graft
    • Congestive heart failure NYHA functional class III or IV
    • Cerebral vascular accident
    • Transient ischemic attack
    • Uncontrolled hypertension at screening
  • Ongoing cardiac arrhythmias of NCI CTCAE grade >=2
  • Active infection requiring antibiotics
  • Pregnancy or breast feeding
  • Prior malignancy within the past 5 years (excluding non-melanoma skin cancer, cervical carcinoma in situ, superficial bladder cancer, and early prostate cancer).
  • Active hepatitis B or C; positive HIV test result.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01922583


Locations
Layout table for location information
Taiwan
National Cheng Kung University Hospital
Tainan, Taiwan, 70403
Department of Oncology, National Taiwan University Hospital
Taipei, Taiwan, 100
Taipei Veterans General Hospital
Taipei, Taiwan, 11217
Sponsors and Collaborators
National Taiwan University Hospital
Investigators
Layout table for investigator information
Principal Investigator: Chih-Hsin Yang, MD, PhD National Taiwan University Hospital

Layout table for additonal information
Responsible Party: National Taiwan University Hospital
ClinicalTrials.gov Identifier: NCT01922583     History of Changes
Other Study ID Numbers: CAUY922ATW02T(201302063MIPD)
1020009413 ( Other Identifier: Taiwan Food and Drug Administration (TFDA) )
First Posted: August 14, 2013    Key Record Dates
Last Update Posted: July 18, 2018
Last Verified: February 2017
Keywords provided by National Taiwan University Hospital:
NSCLC, EGFR mutation
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms